Jiangsu Recbio Technology Co., Ltd. Class H (HK:2179)
:2179
Want to see HK:2179 full AI Analyst Report?
Top Page
Jiangsu Recbio Technology Co., Ltd. Class H
(2179)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$5.00
▲(19.62% Upside)
Action:Reiterated
Date:05/09/26
The score is primarily held back by weak financial performance—volatile revenue, persistent large losses, and ongoing negative operating/free cash flow—despite some improvement in leverage. Technicals add modest support with short-term bullish momentum (price above key short-term averages and positive MACD), but the move looks stretched and remains below the 200-day trend. Valuation is constrained by continued losses (negative P/E) and no dividend support.
Positive Factors
Improving leverage
A meaningful reduction in debt-to-equity reduces immediate financial strain and interest burdens, improving liquidity flexibility. Over the next several months this stronger leverage profile lowers refinancing pressure and gives management more runway to fund R&D, clinical programs, and commercial supply build-outs without urgent capital raises.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flows indicate the business regularly consumes cash to fund operations and investment. This creates ongoing reliance on external financing, raising dilution and refinancing risk. Over months, sustained cash burn constrains investment in commercialization and clinical progress absent new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Improving leverage
A meaningful reduction in debt-to-equity reduces immediate financial strain and interest burdens, improving liquidity flexibility. Over the next several months this stronger leverage profile lowers refinancing pressure and gives management more runway to fund R&D, clinical programs, and commercial supply build-outs without urgent capital raises.
Read all positive factors
Jiangsu Recbio Technology Co., Ltd. Class H (2179) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.87B
Dividend YieldN/A
Average Volume (3M)18.23K
Price to Earnings (P/E)―
Beta (1Y)0.38
Revenue GrowthN/A
EPS Growth0.47%
CountryHK
Employees531
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.15
Shares Outstanding458,092,160
10 Day Avg. Volume1,300
30 Day Avg. Volume18,233
Financial Highlights & Ratios
PEG Ratio0.93
Price to Book (P/B)2.70
Price to Sales (P/S)153.96
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.92
Revenue Forecast (FY)N/A
Jiangsu Recbio Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People's Republic of China. The company is developing vaccines for the treatment of cervical cancer and ...
How the Company Makes Money
null...
Jiangsu Recbio Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
21
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 12.40M | 27.00M | 30.38M | 5.33M | 6.20M |
| Gross Profit | -91.46M | 15.95M | 22.34M | 5.33M | 6.20M |
| EBITDA | -486.44M | -523.97M | -569.87M | -847.67M | -590.00M |
| Net Income | -594.59M | -562.39M | -571.96M | -719.20M | -657.56M |
Balance Sheet | |||||
| Total Assets | 1.76B | 1.94B | 2.19B | 2.31B | 1.92B |
| Cash, Cash Equivalents and Short-Term Investments | 351.99M | 448.31M | 837.76M | 1.33B | 1.18B |
| Total Debt | 638.75M | 889.10M | 650.79M | 282.63M | 76.72M |
| Total Liabilities | 1.06B | 1.41B | 1.12B | 656.53M | 245.92M |
| Stockholders Equity | 706.14M | 529.32M | 1.07B | 1.66B | 1.67B |
Cash Flow | |||||
| Free Cash Flow | -601.50M | -636.66M | -862.18M | -888.04M | -710.79M |
| Operating Cash Flow | -502.64M | -464.82M | -638.07M | -579.54M | -472.92M |
| Investing Cash Flow | 35.43M | -279.04M | 9.42M | -378.43M | 68.70M |
| Financing Cash Flow | 499.77M | 218.06M | 275.27M | 839.44M | 1.23B |
Jiangsu Recbio Technology Co., Ltd. Class H Technical Analysis
Positive
4.18
Price Trends
4.76
Positive
4.77
Positive
5.88
Negative
Market Momentum
0.09
Positive
62.22
Neutral
<0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2179, the sentiment is Positive. The current price of 4.18 is below the 20-day moving average (MA) of 5.15, below the 50-day MA of 4.76, and below the 200-day MA of 5.88, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 62.22 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2179.
Jiangsu Recbio Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$3.51B | -3.96 | -14.53% | ― | -32.12% | -393.23% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$8.25B | 9.33 | 24.17% | ― | 154.21% | ― | |
50 Neutral | HK$12.38B | -11.03 | -64.19% | ― | -33.37% | -344.90% | |
47 Neutral | HK$3.87B | -3.21 | -137.11% | ― | ― | 0.47% | |
44 Neutral | HK$1.79B | -7.60 | -27.70% | ― | -100.00% | 50.29% |
* Healthcare Sector Average
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
5.15
-3.91
-43.16%
HK:1875
TOT BIOPHARM International Co. Ltd.
4.37
2.54
138.80%
HK:2157
Lepu Biopharma Co. Ltd. Class H
4.43
-0.04
-0.89%
HK:2616
CStone Pharmaceuticals
7.70
4.04
110.38%
HK:3681
SinoMab Bioscience Ltd.
1.32
0.04
3.13%
Jiangsu Recbio Technology Co., Ltd. Class H Corporate Events
Jiangsu Recbio Boosts Hong Kong Free Float With Full H-Share Circulation
Apr 30, 2026
Jiangsu Recbio Technology has completed the full circulation of its H shares, converting 141,953,489 previously unlisted shares into H shares that began trading in Hong Kong on April 30, 2026. Following the conversion, the company’s share ca...
Jiangsu Recbio Sets 2025 AGM to Approve Accounts, Budget and Profit Plan
Apr 29, 2026
Jiangsu Recbio Technology Co., Ltd. has convened its 2025 annual general meeting for May 28, 2026 in Taizhou, Jiangsu Province, where shareholders will review the company’s 2025 financial accounts, annual report and board work report, as wel...
Jiangsu Recbio Advances Shingles and HPV Vaccines as 2025 Results Highlight Global Push
Mar 24, 2026
Jiangsu Recbio Technology reported audited annual results for 2025 alongside an update on its advancing vaccine pipeline, underscoring its positioning in high-value prophylactic markets. The company is progressing late-stage candidates targeting s...
Jiangsu Recbio Overhauls Key Governance Posts With New Joint Company Secretaries
Mar 24, 2026
Jiangsu Recbio Technology announced a reshuffle of key governance roles, with the resignation of company secretary, authorised representative and Hong Kong process agent Ms. Yung Mei Yee, effective 24 March 2026. The board noted that Ms. Yung has ...
Jiangsu Recbio Schedules March 2026 Board Meeting on 2025 Results and Dividend
Mar 12, 2026
Jiangsu Recbio Technology Co., Ltd., a PRC-incorporated joint stock company listed in Hong Kong, has a diversified board that includes executive, non-executive and independent non-executive directors, chaired by non-executive director Xu Haoyu. Th...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.